You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. EVENTS - 17-04-2015

    Kedrion supported the XI World Hemophilia Day

    An increasingly tailor-made prophylaxis lets sports and hemorrhagic conditions live together

    read more 
  2. CORPORATE - 27-02-2015

    Kedrion unveils its new manufacturing plant in Castelvecchio Pascoli

    The company has invested over 67 million euros and is expected to create between 70 and 90 new jobs

    read more 
  3. CORPORATE - 16-02-2015

    Kedrion CEO took part in "Italy meets the USA" summit on February 10, 2015

    The NY meeting was aimed at highlighting significant investment opportunities in Italy

    read more 

Pages

For more information please contact: pressoffice@kedrion.com